List of Excipients in Branded Drug CLOMID

Generic Drugs Containing CLOMID

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	clomiphene citrate	0713-0885	LACTOSE MONOHYDRATE
Cosette Pharmaceuticals Inc	clomiphene citrate	0713-0885	MAGNESIUM STEARATE
Cosette Pharmaceuticals Inc	clomiphene citrate	0713-0885	STARCH, CORN

What are the Most Frequently-Used Excipients in CLOMID?

# Of NDCs	Excipient
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE
2	STARCH, CORN

Clomid Excipient Strategy and Commercial Opportunities for Clomiphene Citrate

Last updated: August 9, 2026

Clomid, the original brand of clomiphene citrate, has no meaningful remaining U.S. composition-patent barrier. The commercial opportunity is therefore centered on generic cost reduction, differentiated excipient systems, dosage-form convenience, supply reliability, and regulatory positioning rather than patent exclusivity. Clomiphene citrate is an orally administered nonsteroidal selective estrogen receptor modulator used primarily for ovulatory dysfunction in women who seek pregnancy. The U.S. brand product is no longer the principal commercial channel; generic clomiphene citrate tablets supply the market.[1,2]

What is Clomid and how is clomiphene citrate formulated?

Clomid contains clomiphene citrate, a mixture of the enclomiphene and zuclomiphene stereoisomers. The product is supplied as oral tablets, historically in 50 mg strength. Clomiphene citrate is administered in short treatment cycles, which favors a conventional immediate-release tablet rather than an extended-release system.[1]

The principal formulation requirements are:

• Accurate delivery of a low tablet dose.
• Rapid and consistent disintegration.
• Adequate dissolution across relevant gastrointestinal pH conditions.
• Physical stability during storage.
• Acceptable tablet hardness without delayed drug release.
• Low manufacturing cost for a mature generic market.
• Control of polymorphic, stereochemical, and assay-related API variability.

Clomiphene citrate tablets are generally formulated with conventional excipients such as lactose or another diluent, starch-based disintegrants, magnesium stearate, colloidal silicon dioxide, and tablet coating materials. Exact inactive ingredients differ by manufacturer and must be confirmed against the current product label or DailyMed listing.[2]

What excipients are used in Clomid and generic clomiphene tablets?

The historical Clomid formulation used standard tablet excipients. Generic products can use materially different systems while maintaining the same active ingredient, strength, dosage form, route, and performance requirements.

Excipient function	Common candidate materials	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Tablet mass, flow, compressibility
Disintegrant	Corn starch, sodium starch glycolate, croscarmellose sodium, crospovidone	Rapid tablet breakup
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Granule and tablet strength
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Appearance, swallowability, identification
Color system	Approved synthetic colorants or iron oxides	Product differentiation and light protection

The highest-value excipient decision is usually the diluent-disintegrant combination. Clomiphene tablets contain a relatively small quantity of active ingredient, so blend uniformity and segregation control are more important than API loading efficiency. Direct compression may be attractive when the API and excipient grades provide adequate flow and content uniformity. Wet granulation can offer greater process control where the API has poor flow or segregation risk, but it increases processing cost and introduces moisture and drying variables.

What excipient strategies create commercial opportunities for Clomid generics?

The strongest opportunities involve product attributes that can be supported by manufacturing data, comparative dissolution, and a clear patient or pharmacy benefit.

Lactose-free clomiphene citrate tablets

A lactose-free tablet could address patients with lactose intolerance, excipient preferences, or pharmacy demand for simplified inactive-ingredient profiles. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and selected starch systems can replace lactose, subject to compatibility, dissolution, tabletability, and stability testing.

A lactose-free claim has commercial value only if the formulation is consistently available and clearly labeled. It is unlikely to support a premium by itself in a highly substitutable generic market, but it can help a manufacturer obtain formulary or distributor differentiation.

Dye-free and low-excipient formulations

A dye-free tablet can appeal to patients and prescribers who prefer reduced colorant exposure. A simplified excipient profile can reduce procurement complexity and support a differentiated label. The tradeoff is that color often assists product identification, especially when multiple tablet strengths are sold.

For clomiphene, strength-based packaging, imprinting, and blister configuration can replace some of the identification function of color. A white, film-coated, imprinted tablet may provide a practical dye-free platform.

Direct-compression platforms

Direct compression is the most obvious cost-reduction strategy for a mature immediate-release product. It can reduce granulation steps, solvent use, drying time, and equipment burden. The critical technical risks are:

• API segregation at low drug loading.
• Poor powder flow.
• Variable tablet weight.
• Inadequate tensile strength.
• Lubricant sensitivity.
• Slower dissolution caused by overcompression.

A co-processed excipient containing a filler and disintegrant could improve manufacturability, but the added excipient cost must be justified by reduced process complexity or improved yield.

Rapid-disintegration and smaller-tablet designs

Clomiphene is taken orally over a limited number of treatment cycles. A smaller tablet or rapid-disintegration formulation could improve swallowability and patient acceptance. An orally disintegrating tablet, mini-tablet, or dispersible tablet would require a stronger product rationale because the existing tablet is already a relatively simple dosage form.

A fast-disintegrating product may be commercially relevant for patients who have difficulty swallowing or for fertility clinics that prefer convenient administration. It would also require attention to taste, packaging moisture protection, friability, and dose uniformity.

What formulations are protected by Clomid patents?

The original Clomid patent estate does not provide a current U.S. exclusivity barrier for ordinary clomiphene citrate tablets. The product was approved by the FDA in 1967, and any original composition and basic-use patent rights expired decades ago.[1,3]

Current formulation opportunities may still generate new patents if they contain a genuinely novel and non-obvious technical feature. Potentially protectable subject matter includes:

• A novel particle-size distribution with demonstrated dissolution or stability benefits.
• A specific excipient ratio that improves content uniformity.
• A moisture-protective coating or packaging system.
• A differentiated oral dosage form, such as an orally disintegrating tablet.
• A sustained-release or modified-release product with clinical or pharmacokinetic support.
• A fixed-dose combination with another fertility-related active ingredient.
• A stereoisomer-enriched formulation containing enclomiphene or zuclomiphene.
• A manufacturing process that produces a defined solid-state or impurity profile.

A patent directed only to routine excipient substitution is vulnerable to obviousness and written-description challenges. Stronger protection would require comparative data showing an unexpected result, such as materially improved stability, dissolution, bioavailability, manufacturability, or patient usability.

When does Clomid lose exclusivity and what is the Orange Book status?

Clomid lost meaningful U.S. market exclusivity long ago. The FDA approved Clomid in 1967, and the product is now a mature generic medicine.[1]

Exclusivity issue	Current assessment
Original FDA approval	1967
Current branded U.S. exclusivity	None of commercial significance
New chemical entity exclusivity	Not applicable to current products
Pediatric exclusivity	No known current relevance
Orange Book patent protection	No current basic-product barrier expected
Generic pathway	ANDA for immediate-release tablets
Paragraph IV exposure	Potentially relevant only to later-listed patents, not the original product
Biosimilar pathway	Not applicable

The Orange Book remains the controlling FDA source for listed patents and reference-product information. A sponsor evaluating an ANDA or an alternative formulation must review the current Orange Book entry, FDA-approved labeling, product-specific guidance, and any listed patents associated with the reference product.[3]

Are there Paragraph IV challenges to Clomid?

Paragraph IV litigation is not a major current risk category for conventional clomiphene citrate tablets because the underlying product is old and generic competition is established. A Paragraph IV certification could arise if a later product had an active Orange Book-listed patent, such as a newly approved formulation, delivery system, or method-of-use patent.

For a conventional 50 mg immediate-release tablet, the principal regulatory risk is more likely to involve ANDA approval, bioequivalence, manufacturing quality, product availability, or label differences than an Orange Book patent challenge.

A sponsor should distinguish between:

1. Patents listed in the Orange Book.
2. Unlisted patents that may still be asserted under other legal theories.
3. Method-of-use patents that may be addressed through a Section viii statement.
4. Patent rights covering different stereoisomer products or modified formulations.

What method-of-use patents affect clomiphene citrate?

Clomiphene citrate has been used primarily for ovulatory dysfunction, but clinical practice also includes off-label use in male infertility and hypogonadism-related settings. Off-label use does not itself create FDA-approved method-of-use exclusivity.[1]

A new method-of-use patent could be commercially relevant if tied to:

• A defined patient subgroup.
• A specific dosing schedule.
• A biomarker or diagnostic selection method.
• Combination therapy.
• A clinically differentiated endpoint.
• A novel stereoisomer or formulation.

The commercial value of such a patent would depend on whether the indication is FDA-approved, whether the use is likely to be prescribed, and whether generic labeling can be carved out without undermining the principal market.

How strong is the patent estate for Clomid?

The patent estate for conventional Clomid tablets is weak from an originator-exclusivity perspective and open from a generic-development perspective.

Patent category	Strength for conventional clomiphene tablets
Original composition patent	Expired
Basic oral-tablet formulation	Expired or commercially irrelevant
Original ovulation-induction use	Expired or commercially irrelevant
New excipient formulation	Possible, but requires inventive technical results
Enclomiphene-specific product	Potentially distinct from clomiphene citrate
Modified-release product	Potentially protectable if clinically and technically differentiated
Manufacturing process	Possible protection, with limited blocking power
Packaging and stability system	Possible, usually narrow

The most durable strategy is to pair a formulation patent with regulatory differentiation, supply reliability, and clinical usability. A narrow patent without a meaningful product advantage is unlikely to support significant pricing power.

What FDA regulatory pathway applies to new clomiphene products?

A conventional clomiphene citrate tablet would generally use the ANDA pathway if it references an FDA-approved product and demonstrates pharmaceutical equivalence and bioequivalence.[4] The application must address:

• Active ingredient identity and strength.
• Dosage form and route.
• Inactive ingredients.
• Assay and content uniformity.
• Dissolution.
• Impurities and degradation products.
• Stability.
• Container-closure system.
• Manufacturing controls.
• Bioequivalence, where required.

A new dosage form, new active stereoisomer, or materially different clinical use may require a 505(b)(2) application rather than a standard ANDA. This pathway can support differentiated formulations but generally requires a stronger clinical, pharmacokinetic, or bridging package.

FDA’s inactive-ingredient considerations include route, dosage form, maximum daily exposure, prior use in approved products, and safety information. A novel excipient would create a substantially higher regulatory burden than substituting an established compendial excipient.[5]

What generic entry risks exist for clomiphene citrate?

Generic entry risk is high because the product is old, orally administered, chemically defined, and available in conventional tablet form. The main risks for an entrant are operational rather than patent-based.

Manufacturing and IP barriers

Important barriers include:

• API sourcing and stereoisomer control.
• Impurity specifications.
• Reliable low-dose blend uniformity.
• Scale-up from laboratory granulation to commercial compression.
• Tablet sticking, capping, and friability.
• Dissolution variability across batches.
• Packaging requirements for moisture and light.
• Supplier qualification for critical excipients.
• FDA inspection readiness.

A formulation that depends on a proprietary co-processed excipient could create supply-chain exposure without creating meaningful legal exclusivity. Dual sourcing and a validated substitute excipient system are commercially preferable.

Geographic coverage

U.S. generic entry depends on FDA approval and Orange Book status. Other markets may impose different requirements for reference products, bioequivalence, trademarks, data exclusivity, and patent filings. European, Canadian, Australian, and emerging-market opportunities should be assessed separately because clomiphene may be marketed under different brand names, dosage strengths, and regulatory classifications.

A global excipient platform is most practical when it uses widely accepted excipients with established compendial status. Region-specific colorants, coating agents, or labeling requirements can otherwise force separate formulations.

Which companies are challenging the Clomid market?

The commercial field consists primarily of generic manufacturers and distributors rather than companies competing through a patented Clomid formulation. Generic clomiphene citrate products have been marketed by multiple manufacturers over time, with availability varying by wholesaler, pharmacy channel, and manufacturing status.[2,3]

The principal competitive variables are:

• Wholesale acquisition cost.
• Product availability.
• 50 mg tablet supply.
• Packaging and bottle or blister configuration.
• Excipient restrictions.
• Manufacturer reliability.
• Pharmacy substitution status.
• Contracting with fertility clinics and specialty pharmacies.

There is no biosimilar market because clomiphene citrate is a small-molecule drug, not a biologic. Enclomiphene products, where developed, would represent a mechanistically related but legally and clinically distinct competitive category rather than a biosimilar substitute.

What licensing deals and commercial partnerships affect Clomid?

The mature clomiphene citrate tablet market has limited licensing value because the original product is off-patent and genericized. Commercial partnerships are more likely to involve:

• API supply agreements.
• Contract manufacturing.
• Authorized-generic arrangements.
• Regional distribution.
• Fertility-clinic procurement.
• Co-development of differentiated formulations.
• Enclomiphene or other selective estrogen receptor modulator programs.

A licensing transaction based solely on a conventional clomiphene tablet would require a strong cost, supply, geographic, or regulatory advantage. A formulation license becomes more attractive when it includes issued patents, validated manufacturing data, an FDA filing, or exclusive distribution rights.

What is the revenue exposure and market opportunity for a new Clomid formulation?

Product-specific Clomid revenue is difficult to isolate because the brand has been displaced by generic clomiphene citrate, and public company disclosures often combine products within broader reproductive-health portfolios. A new entrant should therefore model opportunity using prescription volume, net price, channel mix, and supply share rather than historic brand sales.

The most realistic commercial opportunities are:

1. A low-cost, reliable generic tablet.
2. A lactose-free or dye-free product for pharmacy and patient differentiation.
3. A smaller or rapidly disintegrating tablet.
4. A clinic-focused blister pack for cycle-based treatment.
5. A formulation with improved stability in warm or humid markets.
6. A regional product using a validated local manufacturing network.
7. A differentiated stereoisomer product with separate clinical positioning.

Premium pricing is more plausible for a clinically differentiated dosage form than for routine excipient substitution. The generic tablet market will remain price-sensitive, with volume, supply continuity, and manufacturing yield driving returns.

Key Takeaways

• Clomid is a mature, off-patent clomiphene citrate product approved in the U.S. in 1967.
• Conventional 50 mg immediate-release tablets face little current patent-based entry risk.
• Excipient strategy should focus on content uniformity, dissolution, compressibility, stability, and cost.
• Lactose-free, dye-free, smaller, and rapidly disintegrating tablets offer the clearest formulation differentiation.
• New formulation patents require evidence of a non-obvious technical advantage.
• An ANDA is generally appropriate for a conventional generic tablet; a 505(b)(2) pathway may apply to materially differentiated products.
• Biosimilar risk is irrelevant because clomiphene citrate is a small molecule.
• Commercial value depends on reliable supply, manufacturing economics, channel access, and meaningful product differentiation.
• Enclomiphene and other stereoisomer-based products should be analyzed separately from generic clomiphene citrate.

FAQs

Can a lactose-free clomiphene tablet receive patent protection?

Yes, but lactose removal alone is unlikely to provide strong patent protection. A patent would need to claim a novel formulation with a demonstrated technical advantage, such as improved dissolution, stability, content uniformity, or manufacturability.

Is clomiphene citrate suitable for an orally disintegrating tablet?

Potentially. The product is administered orally in a relatively low dose, but taste masking, moisture protection, friability, dose uniformity, and bioequivalence would determine commercial feasibility.

Does clomiphene citrate require a biosimilar application?

No. Clomiphene citrate is a chemically synthesized small molecule. A generic version generally follows the ANDA pathway, subject to FDA requirements.

Could an excipient supplier create a blocking position in the Clomid market?

An excipient supplier could patent a proprietary formulation or co-processed excipient system, but blocking power would depend on claim scope, non-obviousness, enforceability, and whether manufacturers can design around the claims.

Is enclomiphene interchangeable with generic Clomid?

No. Enclomiphene and clomiphene citrate are distinct products. They should not be assumed to be therapeutically, legally, or regulatorily interchangeable without an applicable FDA-approved product and labeling.

References

1. U.S. Food and Drug Administration. (2012). Clomid (clomiphene citrate) tablets: Prescribing information. FDA/DailyMed.
2. National Library of Medicine. (n.d.). DailyMed: Clomiphene citrate tablet product listings. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (2019). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
5. U.S. Food and Drug Administration. (2019). Inactive ingredient database. FDA.